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Abstract
Background: This study intends to develop an efﬁcient ﬁeld‐in‐ﬁeld (FiF) planning
technique with the Eclipse treatment planning system (TPS) to determine the feasibility of using the Halcyon treatment delivery system for 3D treatment of breast
cancer.
Methods: Ten treatment plans were prepared on the Halcyon treatment planning sys-

Funding information
Varian Medical Systems

tem and compared to the same patients’ clinically delivered TrueBeam plans which
used ﬂattened 6 MV and 10 MV beams. Patients selected for this study were treated
via simple, tangential breast irradiation and did not receive radiotherapy of the supraclavicular or internal mammary lymph nodes. Planning target volumes (PTV) volumes
ranged from 519 cc to 1211 cc with a mean target volume of 877 cc. Several planning
techniques involving collimator, gantry rotation, and number of FiF segments were
investigated as well as the use of the dynamically ﬂattened beam (DFB) — a predeﬁned MLC pattern that is designed to provide a ﬂattened beam proﬁle at 10 cm depth
on a standard water phantom. For comparison, the clinically delivered TrueBeam plans
remained unaltered except for normalization of the target coverage to more readily
compare the two treatment delivery techniques.
Results: Using the physician deﬁned PTV, normalized such that 98% of the volume
was covered by 95% of the prescribed dose, the Halcyon plans were deemed clinically acceptable and comparable to the TrueBeam plans by the radiation oncologist.
Resulting average global maximum doses in the test patients were identical between
the TrueBeam and Halcyon plans (108% of Rx) and a mean PTV dose of 102.5% vs
101.6%, respectively.
Conclusions: From this study a practical and efﬁcient planning method for delivering 3D conformal breast radiotherapy using the Halcyon linear accelerator has been
developed. When normalized to the clinically desired coverage, hot spots were
maintained to acceptable levels and overall plan quality was comparable to plans
delivered on conventional C‐arm LINACs.
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6FFF, ﬁeld‐in‐ﬁeld radiotherapy planning, halcyon treatment planning
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placed phantom at 10cm depth. The 6FFF beams used by Halcyon
have ﬂatness values of 10%–20% under the same setup conditions.

Breast carcinoma is the most commonly diagnosed cancer in females.

Using the conventional tangent beam arrangement on a breast target

About one in eight women in the United States (12.4%) will develop

would result in clinically unacceptable dose heterogeneity, usually

invasive breast cancer over the course of their lifetime.1 Radiother-

with large hot spots in excess of 135% of the prescription dose. If

apy, in conjunction with breast conservation surgery and chemother-

the conventional FiF planning technique is directly applied, it typi-

apy, plays a major role in the treatment of these cancers.2 Breast

cally requires a large number of static MLC segments to control the

radiotherapy is typically delivered by conventional 3D beams or

hot and cold spots, increasing the complexity of the plan and

intensity modulated radiation therapy (IMRT). While IMRT is often

required planning time. In this study, we develop and evaluate a

better suited to treat complex targets with involved lymph nodes,3

planning strategy for the Halcyon accelerator to produce clinically

conventional 3D tangent beams continue to make up a large per-

acceptable breast FiF plans using 6FFF beams. Differences in target

centage of radiotherapy treatments with acceptable clinical out-

coverage and organ at risk (OAR) doses as a result of the 6FFF beam
quality were examined as well as patient‐speciﬁc quality assurance

comes and widespread availability.
Recently, a compact ring‐shape medical linear accelerator (LINAC)

(PSQA) delivery and analysis methods.

system, Halcyon (Varian Medical Systems, Inc.), was released. The
Halcyon system provides a single 6FFF beam with double‐stack multi‐leaf collimator (MLC) beam shaping system and faster gantry rotation when compared with conventional C‐arm LINACs. TrueBeam
linear accelerators can deliver treatments at a maximum gantry rota-

2 | METHODS
2.A | Radiotherapy delivery equipment

tion of one rotation per minute vs four rotations per minute with

As shown in Fig. 1(a), Halcyon is a ring gantry LINAC with 100 cm

Halcyon. Maximum dose rate for a ﬂattened 6 MV or 10 MV is

diameter bore size and is capable of providing a 6FFF beam utilizing

600 MU/min at isocenter for TrueBeam and 800 MU/min at isocen-

a compact gantry head design. This compact head allows a 1 m

ter for the 6FFF beam provided on the Halcyon LINAC. Halcyon

diameter patient bore LINAC to be installed in the same room as

was designed to address the global need for access to radiation ther-

required for a conventional C‐arm LINAC. A typical C‐arm LINAC

apy with integrated imaging guidance, improved clinical efﬁciency,

has an effective “bore diameter” of approximately 80 cm, since the

and shorter installation and commissioning time as well as opera-

physical measurement from the treatment head enclosure to

tional demands.4–6 However, the jawless design and unﬂattened

mechanical isocenter is 40 cm. Halcyon employs a staggered, dou-

beam provide some challenges when creating breast 3D plans with

ble‐stack MLC system, as illustrated in Fig. 1(b), which is the only

the FiF techniques. The jawless design might suggest that there is

custom beam shaping device between the x‐ray source and the

increased out‐of‐ﬁeld leakage dose to the patient compared to tradi-

patient. The MLC leaf width is 1.0 cm when projected at isocenter

tional C‐arm accelerators where jaws are needed to minimize this

with 100 cm source‐axis distance (SAD). The proximal and distal lay-

out‐of‐ﬁeld leakage. For example, Varian TrueBeam jaws collimate

ers are offset, or staggered, by 50% of the leaf width such that the

the radiation that is not deﬁned by the MLC aperture and minimize

effective resolution of the leaf stack pair becomes 0.5 cm at isocen-

interleaf leakage (radiation that permeates two adjacent leaves of

ter. The maximum leaf speed is 5.0 cm/s at isocenter with 100%

the same bank). There are two sets, one for each x‐y collimation

interdigitation capability. There are 29 leaf‐pairs leafs in the proximal

direction. They are 78 mm thick along the beam axis and are com-

layer and 28 leaf‐pairs in the distal layer with the maximum ﬁeld size

prised of a tungsten alloy. Halcyon uses a double‐stacked MLC

of 28 × 28 cm2 at isocenter. One of the advantages of the double‐

arrangement with thicker leaves to account for a lack of jaws. The

stack design is that the combined transmission is less than 0.01%,

Millenium‐120 MLCs ﬁtted to most TrueBeams have 67‐mm‐thick

negating the need for physical jaws to reduce peripheral dose to

tungsten leaves, whereas the Halcyon has 77 mm thick leaves in

nontargeted organs.

each bank, creating a combined thickness of 154 mm which results
in an average transmission factor of 0.0047 vs 0.015 for a Millenium‐120 system. Because the MLCs are offset in the direction per-

2.B | Patient selection

pendicular to leaf travel, the interleaf leakage is attenuated by the

Ten breast patients clinically treated with 3D FiF technique on C‐

distal leaf bank. This design with thicker, offset leaves obviates the

arm LINACs (TrueBeam, Varian Medical System) from our institution

need for jaws.

were randomly selected and anonymized. To conﬁne the study to

Typically, the use of 6 or 10 MV ﬂattened beam and a set of sta-

feasibility of utilizing Halcyon for tangential breast radiotherapy,

tic MLC apertures can provide dose uniformity that is clinically

patients with involved supraclavicular, axillary, or internal mammary

acceptable. To better control the dose homogeneity, the ﬁeld‐in‐ﬁeld

lymph node involvement were excluded. Across the 10 patients

7–9

(FiF) technique is also often used in breast 3D planning.

This

selected, two physicians and three dosimetrists were involved in the

method uses multiple, planner‐deﬁned MLC segments that reduce

planning and approval of the treatment plans. This particular selec-

hot spots and improve dose homogeneity. Traditional ﬂattened

tion was performed to minimize potential bias due to a single plan-

beams typically have ﬂatness values under 3% for an isocentrically

ner. The prescribed dose to the PTV was either 4256cGy

16
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2.C | Halcyon FiF plan generation
The Halcyon FiF plans were generated in Eclipse 15.6 treatment
planning system (Varian Medical Systems) with a standardized planning process speciﬁc to our clinic. The overall goal is to create as
few FiF segments in an attempt to balance planning time (<30 min
per patient) and complexity with clinically acceptable target coverage
(V95> 98%), and to minimize the global maximum dose (<115%) relative to the prescribed dose. The following sections 2.3.1‐2.3.5 highlight the key steps and strategies during the planning process

2.C.1 | Field setup
Halcyon planning workﬂow starts with the clinically delivered, physician deﬁned gantry angles and CT simulation‐deﬁned isocenter (mid‐

(a)

bridge). The MLCs are ﬁt to the beams‐eye‐view (BEV) contour of
the PTV with a 0.3 cm isotropic margin. At this point the BEV is
evaluated with the heart and PTV volume visualization turned on.
Typically in clinical plan, the physician will deﬁne the medial block
edge by placing a block margin around the medial aspect of the PTV
with consideration for minimizing heart dose. The block was
designed based on individual patient’s geometry. In this study, we
attempt to develop a simpliﬁed and standardized procedure to test
the feasibility of FiF technique on Halcyon. Therefore, the heart
block was not individually drawn for each patient. Also, at our clinic,
this physician deﬁned block edge is not modiﬁed by the planner,
only MLCs from the other bank are moved to accomplish the FiF
modulation. In this study, we attempt to develop a simpliﬁed and
standardized procedure to test the feasibility of FiF technique on
Halcyon. This is not the case in this study and MLCs from either
bank were used to modulate dose as needed to achieve target cov-

F I G . 1 . (a) Halcyon linear accelerator at Washington University in
St Louis. (b) Detectors‐eye‐view of the lower MLC leaf bank. MLC,
multi‐leaf collimator.

erage and minimize OAR doses. Then approximately 2 cm of ﬂash is
added on the nipple side of the target to account for potential respiratory motion and setup uncertainty (Fig. 2). Dose is then computed
without normalization. Initial hotspots may exceed 140% or be as
low as 95% depending on the patient anatomy. The subsequent

(266cGy × 16 fractions) or 5040cGy (180cGy × 28 fractions). Clini-

planning steps focus on minimizing dose heterogeneity within the

cally, 6 MV beams were utilized for eight of the 10 patients with

beams eve‐view.

10 MV for the remaining two due to increased breast bridge separation (the distance between the medial and lateral borders of the
breast tissue at the middle of the breast). No couch kicks were uti-

2.C.2 | Dynamically ﬂattened beam sequence

lized in the clinical plans for any of the patients selected. Planning

The initial tangent ﬁelds incorporate the use of the TPS dynamically

target volumes (PTV) ranged from 519 cc to 1211 cc with a mean of

ﬂattened beam (DFB) option.10 The DFB is a predeﬁned MLC

877.4 cc. Due to the intrinsic differences in MLC and beam quality,

sequence unique to Halcyon which sweeps the MLCs, whereas the

the Halcyon patients were planned de novo but still using the same

beam is delivering dose to provide a ﬂattened beam proﬁle for a

gantry angles as the TrueBeam plans. Collimator rotation and MLC

ﬁxed gantry beam delivery. This proﬁle, however, is only ﬂattened at

shaped segments as well as respective ﬁeld weighting differed from

depth when delivered on a ﬂat, homogeneous phantom. The DFB

the TrueBeam plans in order to produce homogeneous plans with

sequence does not take into account patient anatomical variations.

the FFF beam quality in as few steps as possible. For dosimetric

The DFB tangents alone did not produce clinically acceptable dose

comparison with the Halcyon FiF plans, the plan normalization was

homogeneity for any of our tested patients (global Dmax < 115% of

the only parameter modiﬁed on the clinically delivered TrueBeam

prescription dose when the PTV was normalized such that

plans. Each plan was normalized such that 98% of the PTV received

V98 = 95%). However, we found that the use of DFB tangents as

at least 95% of the prescribed dose (V95%Rx = 98%).

opposed to non‐DFB tangents markedly reduces the planning time
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(a)

(a)

(b)

(b)

F I G . 2 . (a) BEV of isotropic 0.3 cm margin, circular MLC ﬁt to
PTV. (b) Flash added to anterior MLCs. BEV, beams‐eye‐view; MLC,
multi‐leaf collimator; PTV, Planning target volumes.
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F I G . 3 . BEV of DFB sequence: (a) Proximal bank B (X2) opening
pattern; (b) Proximal bank A (X1) closing pattern. BEV, beams‐eye‐
view.

by reducing the number of manually deﬁned FiF segments that
would be required to achieve a similar, clinically acceptable dose dis-

how the leaf sequence is programmed to produce a ﬂat beam are

tribution.

outside of the scope of this paper. Some details of DFB ﬁeld are

The DFB sequence (Fig. 3) is delivered by starting beam delivery

provided by Constantin et al [10].

with the ﬁeld fully blocked by proximal leaf bank B (X2). During continuous beam‐on, these closed leaves open in a predeﬁned sequence
and park at the opposite ﬁeld edge. Then the leaves of bank A (X1)

2.C.3 | Collimator rotation optimization

initiate their closing sequence until the beam is again fully blocked.

Optimal collimator rotation is needed to aid in subsequent modula-

The DFB sequence is a binary option in the treatment planning sys-

tion of hot spots with the highest resolution achievable with the

tem and has no change in control points as a function of patient

MLC shaping system. A similar concept is used with TrueBeam, but

anatomy, and only varies with ﬁeld size. The number of monitor

is usually slightly different due to the changes in hot spot extent and

units for a DFB ﬁeld is signiﬁcantly increased compared to an open

location as a result of the FFF beam. The optimal rotation is deter-

ﬁeld that would deliver the same dose at treatment depth. This is

mined after the initial dose calculation by analyzing the directions of

because the beam is continuously being delivered while the MLCs

isodose falloff. This refers to the general direction between two or

sweep across so the high‐intensity portion of the beam is blocked to

more isodose lines. Practically, this is better determined through the

make a ﬂat beam. Table 3 in the Results section outlines the overall

use of dose color‐wash visualization in the BEV with the range selec-

MU difference in plans using the DFB vs TrueBeam. Details about

tion slider bar. Mitigation of hot spots with regard to the movement

18
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limitations of the MLC is achieved by setting the collimator rotation

keeping a dosimetrically meaningful number of monitor units (MU)

angle such that the direction of leaf motion is parallel to the isodose

per segment. Institutionally, we have a minimum restriction of 5 MU

falloff at the widest section of the breast in the medial‐lateral direc-

per segment for conventional LINAC FiF planning as well as Step‐

tion, typically at the level of the nipple (Fig. 4). Observed factors that

and‐Shoot IMRT delivery. This reduces the uncertainty due to non-

inﬂuence optimal collimator rotation are breast volume, anatomic tis-

linearities in the delivery of monitor units. The Halcyon FiF planning

sue distribution, and simulation setup conditions including slant

method has adopted this policy.

board angle.

The process of selecting an isodose line as an MLC placement

After optimal collimator angle is determined, the MLCs are re‐ﬁt-

guide is repeated approximately 2–4 times for each tangent ﬁeld at

ted to the PTV with the 0.3 cm isotropic margin and approximately

the initial gantry and collimator rotation angles resulting in 4–8 total

2 cm of ﬂash added by manually selecting and dragging the leaves

FiF segments for the plan. These FiF segments do not utilize the

of the anterior banks for the two DFB tangent beams. Once dose is

DFB feature and are delivered in a step‐and‐shoot fashion with the

recomputed, the ﬁeld weight of the DFB tangents is adjusted such

LINAC in a beam‐hold state during MLC movements. Generally

that the global Dmax is minimized and/or evenly distributed in the

speaking, larger breast volumes will tend to require a higher number

craniocaudal axis.

of FiF segments to control hot spots and improve low dose coverage.

2.C.4 | Manual FiF segments
The initial FiF segment typically utilized only the anterior leaf bank

2.C.5 | Field weighting

for hot spot reduction. For ease of MLC placement, an isodose is

Field weighting is performed after each segment is added and dose

selected that yields a conventional FiF segment size in the BEV. In

recomputed. Weights are locked for all segments delivered at the

our clinic, the planning strategy is to select an isodose that is

same gantry angle such that the FiF segment being weighted trades

approximately 10%–15% lower than the hot spot but this technique

monitor units with the initial DFB tangent beam of the same gantry

does not work well for the 6FFF beam quality and typically results

angle. This method attempts to keep the global hot spots evenly dis-

in a plan that has more FiF segments and required much more time

tributed in the craniocaudal direction. Appropriate ﬁeld weight for

to plan. An “acceptable” FiF segment with this planning strategy

each segment is identiﬁed by actively monitoring the PTV coverage

yields a 1–2 cm collective leaf motion from the previous segment

in the dose volume histogram (DVH) viewer. Initial FiF segments

(Fig. 5). This method attempts to limit the number of segments while

control the high‐dose slope of the DVH curve, whereas the ﬁnal FiF

F I G . 4 . (a) Top row; Planning case in which the optimal collimator rotation was approx. 7 degrees. (b) Bottom row; Planning case in which
collimator rotation was not required.
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dose. Second, portal dosimetry was performed for each ﬁeld. A composite image was created, and gamma criteria was set according to
the recommendations of AAPM task group 218 (3% dose difference,
2 mm distance‐to‐agreement, global normalization, 10% threshold with a tolerance level of 95% of pixels passing).11 Third, the
plans were delivered to a Delta4 Phantom+ (ScandiDos, Sweden).
The same criteria were set as for portal dosimetry on the composite
dose delivered to the phantom.

3 | RESULTS
3.A | Overall plan summary
All Halcyon plans were successfully generated within 30 min following the standardized process developed and were evaluated by a
radiation oncologist that specializes in breast radiotherapy. Overall,
each Halcyon plan tested was deemed clinically acceptable. The
physician evaluated the organs at risk as well as target coverage via
isodose and DVH analysis. Table 1 summarizes the key results for
F I G . 5 . BEV of the initial ﬁeld. An arbitrary isodose line relative to
the maximum dose is chosen as a guide for placement of the MLC
leaves such that approx. 1–2 cm of collective leaf motion results.
BEV, beams‐eye‐view; MLC, multi‐leaf collimator.

PTV dose across all ten patients. As mentioned before, for a fair
comparison, all Halcyon and TrueBeam plans in this study are normalized such that 98% of the PTV volume is covered by 95% of the
prescribed dose. The mean global Dmax is the same for both the
TrueBeam and Halcyon plans (108.0%). The standard deviation for

segments control the low‐dose coverage of the target volume. Fig-

the global Dmax in the plans is 2.5% for TrueBeam and 2.6% for Hal-

ure 6 demonstrates how the shape of the curve changes as a func-

cyon. The mean PTV dose on the TrueBeam plans is hotter (102.5%)

tion of ﬁeld weight for a single initial segment. The optimal ﬁeld

compared with the Halcyon plans (101.6%).

weight will vary based on MLC segment size, patient anatomy, and

OAR doses were analyzed for the heart, ipsilateral lung, and con-

initial dose distribution. This strategy can be applied to all FiF plan-

tralateral lung. The mean dose for all TrueBeam plans was

ning and should be used to minimize the number for FiF segments

97.96 cGy vs 149.58 cGy for the Halcyon plans. The average Dmax

needed and overall planning time.

of the heart for the left‐side target in Halcyon plans is 4450.1 cGy

In our testing, optimal ﬁeld weight tends to straighten the DVH
curve as much as possible while minimizing the high dose tail.

compared to 4403.4 cGy for TrueBeam Plans; the average Dmax for
the heart is 360.0 cGy for Halcyon plans with right‐side target compared to 474.9 cGy for TrueBeam Plans. Mean dose to the con-

2.C.6 | Plan normalization

tralateral lung dose increased from 26.41 cGy to 39.0 cGy for the
Halcyon plans. Ipsilateral mean lung dose decreased using the Hal-

The ﬁnal planning step involves normalization. In this planning study

cyon plans from 676.3 cGy to 569.4 cGy. The mean OAR dose sum-

all patients were normalized such that 98% of the volume was cov-

mary is listed in Table 2.

ered by 95% of the prescribed dose. If the global Dmax was in excess

The mean number of monitor units used for the Halcyon deliv-

of 115% the normalization was reduced until the global Dmax was

ered plans was 732, whereas the TrueBeam delivered plans used

below 115% of prescription. This situation was not encountered

279. In Table 3, it is evident that for larger PTVs (particularly those

with any of the 10 test plans. In clinical practice the target coverage

that were clinically treated with 10 MV) more FiF segments are nec-

and normalization objectives are deﬁned by physician preference. At

essary with the Halcyon LINAC due to the shallower PDD10.

our institution, it is standard practice to achieve a PTV coverage of
V95% = 98% (V95 = 95% minimum acceptable) with a global Dmax less
than 115% (Fig. 7)

3.B | Sample plans
Figures 8 and 9 illustrate the dose distribution and DVH compar-

2.D | Deliverability and plan measurement

isons, respectively, of Halcyon and TrueBeam plans for test patient
05. This test plan is representative of a typical Halcyon plan in terms

In order to test the deliverability of the ten plans, PSQA was per-

of resultant coverage and global Dmax. This patient had a bridge

formed on each plan. First, ion chamber measurements were taken

separation of 19 cm and a PTV volume of 687 cc which is within

with a PTW 31010, in a solid water phantom (15 cm3). Passing crite-

one standard deviation (257 cc) of the average PTV volume of the

ria were percent dose deviation of less than ±3% from the expected

patients tested (877.4 cc). Qualitatively, the Halcyon plan has a more

20
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F I G . 6 . (a) Initial DVH of PTV for patient 05 using various ﬁeld weights for the ﬁrst 2 FiF segments. (b) Zoomed view of high dose region of
DVH in Figure 6. For this segment, 4% ﬁeld weight was optimal but optimal ﬁeld weights will vary from patient to patient as well as segment
to segment. DVH, dose volume histogram; PTV, Planning target volumes.

F I G . 7 . DVH comparison of PTV
coverage using 6FFF tangent beams alone,
the DFB tangents alone, and the DFB
tangents paired with the manual FiF
segments. All three plans were normalized
such that 98% of the PTV volume was
covered by 95% of prescription. DFB,
dynamically ﬂattened beam; DVH, dose
volume histogram; PTV, Planning target
volumes.
uniform dose in all three anatomical planes. The global Dmax was

in Figure 9 shows comparable PTV coverage and OAR sparing

1.5% lower (105.9% vs 104.4%). Ipsilateral mean lung dose

between the two plans. Overall, the Halcyon plan only incorporated

decreased from 375 cGy to 310 cGy, a 17.3% reduction. The DVH

1 more FiF segment compared to the TrueBeam plan (4 vs 3) (10).

MORRIS
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T A B L E 1 Summary of Test Patient Results — PTV dose.
Patient

PTV volume

Site laterality

TB Global Dmax

H Global Dmax

TB mean PTV

H mean PTV

1

1069 cc

Right

106.7%

111.5%

101.1%

102.9%

2

709 cc

Left

108.8%

110.3%

103.3%

103.3%

3

519 cc

Left

109.1%

106.6%

103.6%

99.8%

4

909 cc

Right

106.4%

108%

103.1%

102%

5

687 cc

Right

105.9%

104.4%

100.5%

100.5%

6

566 cc

Left

113.2%

105.1%

107.3%

100.9%

7

1174 cc

Right

105.1%

105.7%

99.9%

99.8%

8

801 cc

Right

106.4%

107.2%

99.8%

101.5%

9

1129 cc

Left

107.6%

111%

103.1%

101.6%

10

1211 cc

Right

110.9%

110.3 %

103.7%

103.2%

Average

877.4 cc

40% Lt 60% Rt

108.0%

108.0%

102.5%

101.6%

Standard Deviation

257.4 cc

n/a

2.5%

2.6%

2.3%

1.3%

PTV, planning target volumes.

T A B L E 2 Summary of Test Patient – mean OAR dose.
Patient

PTV Volume

TB mean Heart
(cGy)

Hal mean Heart
(cGy)

TB mean Ipsil. Lung
(cGy)

Hal mean Ipsil.
Lung (cGy)

TB mean Cont.
Lung (cGy)

Hal mean Cont.
Lung (cGy)

1

1069 cc

46.8

2

709 cc

225.6

55.3

540.5

332.0

4.3

8.5

353.2

574.6

583.1

170.2

187.3

3

519 cc

205.0

345.0

4

909 cc

45.0

70.0

735.0

745.0

20.0

40.0

610.0

460.0

5.0

15.0

5

687 cc

38.3

59.6

940.6

889.5

4.3

12.8

6

566 cc

149.0

280.9

919.3

872.5

8.5

25.5

7

1174 cc

46.8

63.8

740.5

655.4

34.0

46.8

8

801 cc

4.3

21.3

757.6

297.9

4.3

12.8

9

1129 cc

155.0

170.0

375.0

310.0

5.0

20.0

10

1211 cc

63.8

76.6

570.3

549.0

8.5

21.3

Average

877.4 cc

97.96

149.58

676.34

569.44

26.41

38.99

Std.
Dev.

257.4 cc

78.27

129.01

175.84

221.73

51.44

78.27

TB, TrueBeam; Hal, Halcyon; PTV, planning target volumes.

T A B L E 3 Energy, MU, and Segments used.
Patient

PTV Volume

TB Energy

Hal Energy

TB FiF Segments

H FiF Segments

TB MU

Hal MU

1

1069 cc

6 MV

6FFF

5

7

302 MU

796 MU

2

709 cc

6 MV

6FFF

5

5

328 MU

736 MU

3

519 cc

6 MV

6FFF

4

6

244 MU

557 MU

4

909 cc

10 MV

6FFF

4

6

223 MU

574 MU

5

687 cc

6 MV

6FFF

3

4

300 MU

739 MU

6

566 cc

6 MV

6FFF

3

4

309 MU

713 MU

7

1174cc

6 MV

6FFF

6

6

306 MU

828 MU

8

801 cc

6 MV

6FFF

5

6

310 MU

844 MU

9

1129 cc

10 MV

6FFF

4

8

224 MU

677 MU

10

1211 cc

6 MV

6FFF

5

6

239 MU

857 MU

TB, TrueBeam; Hal, Halcyon; PTV, planning target volumes.
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Qualitative analysis for patient 05: Bridge separation = 19 cm. PTV Volume = 687 cc. PTV, planning target volumes

F I G . 9 . DVH comparison for patient 05:
Bridge separation = 19 cm. PTV
Volume = 687 cc. DVH, dose volume
histogram; PTV, planning target volumes.
Figures 11 and 12 illustrate the dose distribution and DVH comparisons, respectively, for the most difﬁcult plan encountered across

plans passed 3%/2 mm with 100% points passing. Average Delta4
passing rate was 99.4%.

the 10 test patients. This patient had a bridge separation of 26 cm and
a PTV volume of 1129 cc which was the largest bridge separation and
second largest PTV volume in the study. This patient was clinically

4 | DISCUSSION

treated using only 10MV beams. Qualitatively, the Halcyon does have
a less uniform dose but a clinically comparable PTV coverage based on

We demonstrated a FiF breast planning strategy utilizing a 6FFF

the DVH. The global Dmax was 3.7% higher (105.6% vs 109.7%). Ipsi-

beam on the Halcyon platform. All ten plans were determined clinical

lateral mean lung dose decreased from 941 cGy to 890 cGy, a 5.4%

acceptable. Conventionally, FFF beams have not typically been used

reduction. The DVH in Figure 12 shows comparable PTV coverage

in breast 3D planning due to the insufﬁcient ability to deliver homo-

and OAR sparing between the two plans. Overall, the Halcyon plan

geneous dose to targets at depth. However, the percent‐depth‐dose

only incorporated 4 more FiF segments compared to the TrueBeam

(PDD) for both 6 MV ﬂattened (TrueBeam) and unﬂattened (Hal-

plan (4 vs 8) (13).

cyon) beams on central axis (CAX) are very similar to one another.
The PDD at a 10 cm depth with a 10 × 10 cm2 ﬁeld size and

3.C | Deliverability and Plan QA

100 cm source‐to‐surface distance (SSD) for a 6 MV ﬂattened beam
is nominally 66.7% vs 63.2% for a 6FFF beam. For comparison, a

All FiF plans were successfully delivered on Halcyon. Table 4 shows

10 MV beam has a nominal PDD of 73.2% under the same setup

the ion chamber measurements and gamma passing rates for all ten

conditions. This similar beam quality gives rise to the hypothesis that

plans. The average IC measurement had a percent dose deviation of

with proper beam modulation, the nonﬂattened proﬁle of a 6FFF

1.51% with the maximum deviation of 2.23%. All portal dosimetry

beam can be used to yield acceptable target heterogeneity while

MORRIS
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F I G . 1 0 . BEV of the DFB and FiF segments for patient 05: Bridge separation = 19 cm. PTV Volume = 687 cc. BEV, beams‐eye‐view; DFB,
dynamically ﬂattened beam; PTV, planning target volumes.

FIG. 11.

Qualitative analysis for patient 09: Bridge separation = 26 cm. PTV volume = 1129 cc. PTV, planning target volumes.

limiting hot spots of dose outside the targeted breast with a FiF

that makes best use of the technique available to the user of Hal-

technique. This was even demonstrated for two patients that were

cyon linac and to test the feasibility of applying FiF technique to

clinically treated with 10 MV beams to achieve the deep depth tar-

breast patient with jawless design and DSMLC (Double‐Stack MLC).

get coverage without exceeding physician deﬁned global Dmax con-

Therefore, we are not expecting to exactly mimic all beam parame-

straints. The focus of this paper is to establish a planning strategy

ters as in clinical plans. The purpose of showing TrueBeam data is
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F I G . 1 2 . DVH comparison for patient
09: Bridge separation = 26 cm. PTV
Volume = 1129 cc. DVH, dose volume
histogram; PTV, planning target volumes.

F I G . 1 3 . BEV of the DFB and FiF segments for patient 09. Bridge separation = 26 cm. PTV Volume = 1129 cc. BEV, beams‐eye‐view; PTV,
planning target volumes.

not to determine which planning technique or modality is better
rather than providing some clinical references.
The primary organs at risk evaluated in this study were the heart,

The contralateral lung dose was also higher with the Halcyon
plans by an average of 12.6 cGy (39.0 cGy vs 26.4 cGy). The uncertainty in this value, however, is too high to make any deterministic

ipsilateral lung, and contralateral lung. The mean heart dose

conclusions. It is well‐known that the uncertainty in calculating out

increased by an average of 51.6 cGy using the Halcyon plans

of ﬁeld dose predicted by modern day treatment planning systems is

(98.0 cGy vs 149.6 cGy). Dmax to the heart for left sided targets

very high,12 especially at distances in excess of 10 cm from the ﬁeld

increased by 46.7 cGy (4403.4 cGy vs 4450.1 cGy) and Dmax

edge. The accuracy of predicting peripheral doses with the Halcyon

decreased for right sided targets by 114.9 cGy (474.9 cGy vs

TPS has also not yet been thoroughly evaluated.

360.0 cGy). This was due to the initial planning strategy of ﬁtting

Mean dose to the ipsilateral lung decreased with the Halcyon

the primary DFB beams to the PTV with an arbitrary, isotropic

plans by 15.8% (569.4 cGy vs 676.3 cGy). Similarly to the heart

0.3 cm margin. This was chosen to simplify and standardize the plan-

dose, this result could be a function of the isotropic 3 mm margin

ning process for this study. When visualized in the treatment plan-

used in this study. However, the BEV of the clinical TrueBeam vs

ning system beams‐eye‐view, part of the heart is exposed to

Halcyon plans is nearly identical when evaluating the block edge

the direct beam in the Halcyon plans as a result of this 0.3 cm mar-

relative to the lung/chest wall interface. The softer spectrum of

gin. In clinical practice, the physician would aid the dosimetrist in

the 6FFF beam is the likely explanation to decreased ipsilateral

deﬁning the block edge between the ipsilateral lung, heart and PTV.

lung dose. It is evident that the isodoses near the isocenter dip

With the individually designed heart block, the heart dose can be

toward the chest wall much more than the TrueBeam 6 MV and

further reduced in the Halcyon plans.

10 MV plans. Lateral scatter and increased attenuation from the
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T A B L E 4 Patient‐speciﬁc QA results (%).
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breast plans. On Halcyon, however, since we are using DFB techD4 Gamma
Passing Rate (%)

nique, we propose to perform measurement‐based patient‐speciﬁc

Patient

IC Point Dose
Deviations (%)

PD Gamma
Passing Rate (%)

1

1.48

100

2

0.61

100

3

0.60

100

4

1.90

100

100

5

2.06

100

100

6

1.61

100

98.7

7

1.42

100

98.8

8

1.98

100

99.0

9

1.20

100

99.4

10

2.23

100

99.2

patible even with the 100 cm diameter physical bore size. From this

Average

1.51

100

99.4

planning study, for bridge separation distances exceeding 26 cm, it is

98.9
100
99.5

IC = ion chamber, PD = portal dosimetry, D4 = Delta4. Dose difference
criteria was 3%, distance to agreement was 2 mm, and 95% gamma
passing rate.

QA, like IMRT cases, as our secondary check. Therefore, there is no
direct comparison with clinical plans on measurement‐based QA. As
Halcyon is still a relatively new modality and DFB is a new technique, we proposed to use measurement‐based patient‐speciﬁc QA
for the FiF plans in this study. This does require extra machine time
and effort from the physics and QA team compared to traditional
FiF plans on TrueBeam machines. It is also important to note that
not all breast cancer patients would be eligible for treatment on the
Halcyon unit. The maximum ﬁeld size on halcyon is 28 × 28 cm2 at
isocenter, therefore patients with a large target size might not ﬁt
into the beam portal design. Obese patients may also not be com-

difﬁcult to achieve adequate coverage at depth with the 6FFF beam
quality. In conventional multi‐port 3D breast radiotherapy, additional
ﬁelds are used to treat involved lymphatics such as the axillary, supraclavicular, and internal mammary lymph nodes. Historically, couch

medial and lateral lung regions are the most likely causes of a

kicks (rotation of the treatment couch relative to the gantry) are

reduction in ipsilateral lung dose when utilizing a 6FFF for breast

used to match ﬁeld edges to avoid potential under or over‐dosage of

radiotherapy.

normal and targeted tissues. Halcyon is currently not capable of

The Halcyon FiF plan requires more MU due to the use of DFB.

rotating the couch to match beam divergence. One historic alterna-

However, this will not increase the treatment delivery time com-

tive to couch rotations is the half‐beam block technique.3 This tech-

pared to TrueBeam plan. The ring gantry on Halcyon has the capabil-

nique utilized the jaws to eliminate beam divergence by placing one

ity to rotate faster at four rotations per minute (RPM) vs 1 RPM for

of the jaws at the center of the ﬁeld which will abut subsequent

a conventional TrueBeam. The dose rate is also higher (800 MU/min)

treatment ﬁelds. The fact that Halcyon is jawless does not prevent

than that of a 6 MV ﬂattened beam (600 MU/min) on TrueBeam.

an equivalent approach using the onboard MLC. Leakage is signiﬁ-

For the 10 patients tested, the computed delivery time based on

cantly reduced but not eliminated by the Halcyon MLCs compared

average the MU per plan and gantry rotation speed was 62.4 s for

to the Millenium‐120 which is standard on most TrueBeams. The

Halcyon and 57.9 s for TrueBeam. The MLC movement speed was

biggest challenge of Halcyon compared to TrueBeam is the reduced

not accounted for in this study but is not expected to drastically

ﬁeld size at isocenter paired with the increased limitations in isocen-

change the previously mentioned delivery times. Setup times for

ter placement due to the physical bore. Future work will include

IGRT treatments will also affect total patient treatment times. Portal

investigation of using Halcyon to treat these complex breast cases.

images typically used for patient alignment pretreatment are not
available on the Halcyon. The options for imaging patient setup
include: MV 2D/2D (AP and Lateral), MVCBCT, and kVCBCT. Only

5 | CONCLUSION

one option can be chosen during planning and it must be performed
daily. Due to the kVCBCT’s lower imaging dose and fast acquisition
time (as low as 16.7 s), we anticipate its wide usage. Image acquisition for Halcyon thus is faster than TrueBeam due to the fourfold
6

increase in gantry rotation speed. In conclusion, treatment delivery
times should be comparable between both treatment machines given
that patient setup times are signiﬁcantly longer than beam on times
for this type of treatment.
Some limitations to this planning method exist. Firstly, only ten
patients’ plans were evaluated, although these ten patients reﬂect a
good laterality and PTV volume distribution, more cases will be
investigated in a future study to further characterize the beneﬁts

In this study, a practical and efﬁcient planning method for delivering
3D conformal breast radiotherapy using the Halcyon linear accelerator has been developed. When normalized to the clinically desired
coverage, hot spots were maintained to acceptable levels and overall
plan quality was comparable to plans delivered on conventional C‐
arm LINACs. Using the original isocenter and gantry angles that were
used for TrueBeam delivery, the Halcyon patients would not have
experienced clearance issues as indicated by the TPS. Intrinsically,
the 6FFF beam’s slightly shallower PDD did not prohibit its use for
achieving deep target coverage while keeping superﬁcial hot spots
below 115% of prescription.

and limitations of breast 3D FiF planning with Halcyon. All Halcyon
FiF plans passed the QA indicated the feasibility of the actual deliv-
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